Treating Restless Leg Syndrome with Ferric Carboxymaltose

Treating Restless Leg Syndrome with Ferric Carboxymaltose

This month we are dissecting an article from Sleep Medicine, the official journal of the World Sleep Society and International Pediatric Sleep Association – Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia.

Treatment guidelines for Restless Leg Syndrome (RLS) advocate for using iron therapy when peripheral iron levels are low, however, they don’t address treatment with concomitant iron deficiency anemia. Join us for this month’s Journal Club as we evaluate iron studies and recommend appropriate oral/parenteral iron dose and frequency for RLS.

Upon successful completion of this application-based course, participants should be able to:
1. Evaluate the clinical and statistical significance of a study examining the use of Ferric Carboxymaltose (FCM) in patients with Restless Leg Syndrome (RLS) and concomitant Iron Deficiency Anemia (IDA)
2. Determine appropriate laboratory tests (iron indices) which may be used to identify patients with IDA and RLS who are candidates for a trial of FCM administration
3. Use a validated scale to assess patient response to FCM when used to treat RLS + IDA
4. Create a treatment regimen for a patient with RLS + IDA using FCM 

Justin Hooper, RPh, PharmD, BCPS
Corporate Director
Justin Hooper reports that he is a Clinical Advisory Board member for HealthTrust Purchasing Group.

ARTICLE: Bae H, Cho YW, Kim KT, Allen RP, Earley CJ. Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia. Sleep Med. 2021 Aug;84:179-186. doi: 10.1016/j.sleep.2021.05.036. Epub 2021 Jun 20. PMID: 34157632.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: February 9, 2022
Planned Expiration Date: February 9, 2025 

Copyright 2022, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  


Universal Activity Number (UAN): 0107-0000-22-033-H01-P
Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information


1h 0m

Topic Designator

Disease State/Drug Therapy



ACPE Topic

01 Drug Therapy





Release Date






ACPE Number


This course is in our subscription.